Sagimet Biosciences announces positive topline results from phase 2b trial of denifanstat
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated